article · Tropical Journal of Pharmaceutical Research
Purpose: To investigate the antibacterial activity of a partially purified ethyl acetate fraction obtained from methanol extract of the root bark of Terminalia avicennioides (Family: Combretaceae) against a hospital strain of methicillinresistant Staphylococcus aureus (MRSA).Methods: Gas chromatography-mass spectrometry (GC-MS) was used to identify and characterize compounds in the bioactive fraction of T. avicennioides root bark, while Fourier Transform Infrared (FTIR) spectroscopy was used to elucidate the functional groups. The MRSA hospital strain was isolated from a clinical sample and the isolate biochemically characterized by colonial morphology, Gram staining, and strain reaction. Resistance to methicillin/oxacillin was confirmed by repeat susceptibility testing using oxacillin. The antibacterial efficacy of the fraction was compared with those of standard antibiotics including meropenem, amoxiclav, nitrofurantoin, ceftriaxone, nidof, and ciprofloxacin. Antimicrobial activity was evaluated using agar well diffusion method, while the minimuminhibitory concentration (MIC) was determined using a 10-fold serial broth dilution assay.Results: Mass spectrometry analysis revealed that the ethyl acetate fraction with anti-MRSA activity comprised a mixture of seven compounds in varying proportions, viz: n-hexadecanoic acid, 11-octadecenoic acid, oleic acid, octadecanoic acid, 3,11-tetradecadien-1-ol, 9-octadecenal, and (9Z)-9-tetradecenal. The FTIR spectra indicated the presence of alkyl halides. At 100 μg/mL, the ethyl acetate fraction exhibited a bacteriostatic effect, with a minimum bactericidal concentration (MBC) of 9.48 ± 0.90 μg/mL. Based on Kirby-Bauer standard, it demonstrated bactericidal activity (MBC) at 150 μg/mL, with mean inhibition zone diameter of 14 mm.Conclusion: The synergistic action of the seven identified compounds in the bioactive fraction may offer a promising foundation for developing novel drug candidates with potent bactericidal activity against hospital-acquired MRSA strains.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.4314/tjpr.v24i6.4
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
